"Pershing Square, which is working with Valeant Pharmaceuticals on a $53 billion hostile bid for the Botox maker Allergan, is still working to secure enough shareholder support to call a special meeting. Should the meeting be called, Pershing Square, which owns about 10 percent of Allergan, will attempt to dismiss without cause six existing board members, and elect six new ones." - New York Times